Conclusion: Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs. A large ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly ... turnover of CHF 2.7 billion ($2.95 billion) last year. The drug has long been a major earner for the Swiss group but ...